Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination

Eculizumab inhibits terminal complement-mediated intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and complement-mediated thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome and is now used as a first-line therapy in these diseases. Eculiz...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biol Blood Marrow Transplant
Autors principals: Jodele, Sonata, Dandoy, Christopher E., Danziger-Isakov, Lara, Myers, Kasiani C., El-Bietar, Javier, Nelson, Adam, Wallace, Gregory, Teusink-Cross, Ashley, Davies, Stella M.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705021/
https://ncbi.nlm.nih.gov/pubmed/27060440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2016.03.032
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars